| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $12,258,450 | 23 | 100 |
| Dhaliwal Harpreet S. | Chief Technical Ops Officer | 0 | $0 | 2 | $1.39M | $-1.39M |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | 0 | $0 | 3 | $1.64M | $-1.64M |
| Cowan Elvia | SVP, FINANCE | 0 | $0 | 5 | $2.64M | $-2.64M |
| Wassil Jim | CHIEF OPERATING OFFICER | 0 | $0 | 10 | $3.01M | $-3.01M |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 0 | $0 | 3 | $3.58M | $-3.58M |
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer …
Over the last 12 months, insiders at Vaxcyte, Inc. have bought $0 and sold $12.26M worth of Vaxcyte, Inc. stock.
On average, over the past 5 years, insiders at Vaxcyte, Inc. have bought $0 and sold $17.98M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 186,000 shares for transaction amount of $2.98M was made by Hopfner Robert Lorne (director) on 2020‑06‑16.
| 2026-10-05 | Sale | Wassil Jim | EVP, Chief Scientific Ofc, COO | 18,000 0.0146% | $86.74 | $1.56M | -13.82% | |
| 2026-10-05 | Sale | Cowan Elvia | SVP, Finance & CAO | 19,000 0.0155% | $86.74 | $1.65M | -13.82% | |
| 2026-10-01 | Sale | Wassil Jim | EVP, Chief Scientific Ofc, COO | 2,250 0.0016% | $56.67 | $127,513 | +13.51% | |
| 2026-09-09 | Sale | Wassil Jim | EVP, Chief Scientific Ofc, COO | 1,334 0.0009% | $59.52 | $79,401 | +1.87% | |
| 2026-09-04 | Sale | Wassil Jim | EVP, Chief Scientific Ofc, COO | 1,381 0.001% | $61.16 | $84,462 | -1.19% | |
| 2026-09-01 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 3,477 0.0024% | $61.07 | $212,352 | -0.27% | |
| 2026-08-05 | Sale | Dhaliwal Harpreet S. | Chief Technical Ops Officer | 17,000 0.0116% | $55.00 | $935,068 | +8.40% | |
| 2026-08-03 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 2,250 0.0016% | $53.86 | $121,195 | +12.89% | |
| 2026-08-03 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 10,000 0.0072% | $53.89 | $538,879 | +12.89% | |
| 2026-07-27 | Sale | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 18,198 0.0126% | $55.63 | $1.01M | +8.63% | |
| 2026-07-06 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 10,000 0.0068% | $57.28 | $572,837 | +4.53% | |
| 2026-07-01 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 2,250 0.0016% | $56.33 | $126,736 | +6.12% | |
| 2026-06-26 | Sale | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 24,237 0.0173% | $55.22 | $1.34M | +5.00% | |
| 2026-06-18 | Sale | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | 23,461 0.0168% | $52.50 | $1.23M | +14.74% | |
| 2026-06-18 | Sale | GUGGENHIME ANDREW | PRESIDENT AND CFO | 10,000 0.0072% | $53.00 | $530,000 | +14.74% | |
| 2026-05-01 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 2,250 0.0016% | $56.83 | $127,870 | +1.67% | |
| 2026-04-07 | Sale | Cowan Elvia | SVP, Finance & CAO | 3,000 0.0021% | $60.00 | $180,000 | -4.04% | |
| 2026-04-01 | Sale | Wassil Jim | CHIEF OPERATING OFFICER | 2,250 0.0016% | $58.43 | $131,476 | -0.36% | |
| 2026-03-17 | Sale | Cowan Elvia | SVP, Finance & CAO | 1,892 0.0013% | $55.57 | $105,147 | +4.76% | |
| 2026-03-11 | Sale | Cowan Elvia | SVP, Finance & CAO | 2,500 0.0018% | $58.59 | $146,482 | +0.94% |
| TPG Group Holdings (SBS) Advisors, Inc. | 5074574 3.2242% | $308.58M | 1 | 1 | <0.0001% | |
| EMSTER KURT VON | director | 4168718 2.6487% | $253.5M | 1 | 0 | <0.0001% |
| Heron Patrick J | director | 2309554 1.4674% | $140.44M | 1 | 0 | <0.0001% |
| Hopfner Robert Lorne | director | 1405418 0.893% | $85.46M | 1 | 21 | <0.0001% |
$159,914,414 | 243 | 18.52% | $8.86B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$323,530,732 | 48 | 29.90% | $21.42B |
| Increased Positions | 162 | +46.69% | 19M | +13.52% |
| Decreased Positions | 157 | -45.24% | 14M | -9.61% |
| New Positions | 66 | New | 5M | New |
| Sold Out Positions | 48 | Sold Out | 3M | Sold Out |
| Total Postitions | 352 | +1.44% | 148M | +3.91% |
| Janus Henderson Group Plc | $608,821.00 | 10% | 13.1M | -2M | -10.8% | 2025-09-30 |
| Fmr Llc | $581,211.00 | 9.55% | 12.51M | +358,883 | +2.95% | 2025-09-30 |
| Vanguard Group Inc | $572,408.00 | 9.4% | 12.32M | +323,368 | +2.69% | 2025-09-30 |
| Ra Capital Management, L.P. | $555,940.00 | 9.13% | 11.97M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $462,555.00 | 7.6% | 9.96M | -686,265 | -6.45% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $386,329.00 | 6.35% | 8.32M | +2M | +38.56% | 2025-09-30 |
| Wellington Management Group Llp | $233,823.00 | 3.84% | 5.03M | +77,967 | +1.57% | 2025-09-30 |
| State Street Corp | $222,352.00 | 3.65% | 4.79M | -156,346 | -3.16% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $199,350.00 | 3.28% | 4.29M | +1M | +38.93% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $175,840.00 | 2.89% | 3.78M | +411,918 | +12.21% | 2025-09-30 |